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Previous reports suggest feasibility of autologous transplantation
for HIV-associated lymphomas. Anecdotal reports suggest that
allogeneic hematopoietic stem cell transplantation (AlloHCT) also
may be feasible. To evaluate AlloHCT in HIV-positive patients,
we retrospectively analyzed 30 HIV-positive patients with malig-
nant (n22) or non-malignant disorders (n8), who received Al-
loHCT between 1987 and 2003 and were reported to the CIB-
MTR.
The median age at transplant was 34 years (range 9-49) and the
donors were: HLA identical siblings, 21 (70%); syngeneic, 5
(17%); and unrelated, 4 (13%). Indications for HCT included:
non-Hodgkin lymphoma, 11; chronic myeloid leukemia, 3; acute
myeloid leukemia, 3; myelodysplastic syndrome, 2; acute lympho-
blastic leukemia, 2; other acute leukemia, 1; aplastic anemia, 2; and
other non-malignant disorders including HIV disease, 6. Twenty-
two (73%) patients were transplanted prior to 1996. The condi-
tioning regimens included total body irradiation (TBI) containing,
16 (53%); and chemotherapy only, 14 (47%).
Rate of neutrophil engraftment at 28 days was 76%. The cumu-
lative incidence (95% CI) of grades II – IV acute GVHD (synge-
neic excluded) was 9% (1 – 23). For patients alive at 100 days (n 
12), the cumulative incidence of chronic GVHD at 1 and 2 years
was 42% (17 – 69). At a median follow-up of 55 months, 6 patients
are alive with a survival probability of 20% (10-33) at 2-years.
Treatment related mortality (TRM) at 100 days and 2-years were
46% (29 – 65) and 68% (50 – 84), respectively. Causes of TRM:
pulmonary toxicity, 8; infections, 4; organ failure, 4; HIV disease,
2; and others, 3. Deaths related to pulmonary toxicity appear to be
higher in patients receiving TBI based conditioning (6/16) com-
pared to the other conditioning regimens (2/14).
Of the available CD4 counts (x109/L) and viral loads (log copies)
data, median CD4 count (n  11) and viral load (n8) prior to
BMT was 137 and 2.1, respectively. At 3 months post BMT, the
median CD4 count (n 16) was 29. After 6 months post BMT, the
median CD4 count (n  9) and viral load (n  10) were 640 and
1.7, respectively.
Of the 8 patients transplanted after 1996, 4 survive compared to
2 of 22 transplanted prior to 1996, presumably related to the effect
of improved supportive care and HAART. These data suggest that
AlloHCT is feasible for HIV-positive patients with malignant and
non-malignant disorders and provide the framework for the design
of future prospective studies.
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A NEW STRATIFICATION STRATEGY THAT IDENTIFIES A HIGH RISK
SUBSET OF CLASS III PATIENTS AMONG CHILDREN WITH  THALAS-
SEMIA MAJOR UNDERGOING A MATCHED RELATED ALLOGENEIC STEM
CELL TRANSPLANTATION
Mathews, V.1, George, B.1, Lakshmi, K.M.1, Viswabandya, A.1,
Chandy, M.1, Srivastava, A.1 1Christian Medical College, Vellore,
Tamil Nadu, India.
The current risk stratiﬁcation of patients with  thalassemia major
undergoing an allogeneic SCT is based on liver size (2cm), presence
of liver ﬁbrosis and inadequate iron chelation (Lucarelli et al, NEJM
1990). Our clinical observation suggested that patients in Class III
(presence of all three adverse features) were a heterogeneous group.
We undertook a retrospective analysis to study the pre-transplant
variables that have an impact on outcome. Between 1991 and 2005,
190 patients underwent 197HLAmatched related allogeneic SCT for
a diagnosis of  thalassemia major at our center. Except for two cases,
all patients’ were less than 18 years of age at the time of transplant.
The majority (97.5%) of patients received a myeloablative (BuCy)
conditioning regimen. The median (	SD) age of this cohort was
7	4.1 years with 68% males. There were 11(5.6%), 81(41.1%) and
105(53.3%) in Lucarelli Class I, II and III respectively. The Kaplan-
Meier 5 year event free survival (event deﬁned as rejection, relapse or
death) for Class II and III patients’ was 78.53	4.53 and 51.97	5.14,
respectively. Only patient age and liver size as continuous variables
were signiﬁcantly associated with an adverse outcome. Using a ROC
curve plot analysis, cutoff values of 7 years and 5 cms respectively for
age and liver size gave the highest likelihood ratios for an adverse
effect on EFS (1.6 and 2.7 respectively). These cut off values signiﬁ-
cantly discriminated patients’ EFS on a univariate analysis. On a
forward stepwise multivariate analysis only age 7 years and liver
size  5 cms retained their signiﬁcance (RR 2.2 and 3.6, P-values
0.014 and 0.000 respectively). Using these two variables patients were
categorized as high risk if they were  7 years and had a liver size 
5 cms. There were 41 cases in this sub group (all were Class III). The
5 year EFS and OS in this high risk group (n41) was 23.93	6.88
and 39.01	7.96 while in the remaining Class III cases (n64) the 5
year EFS and OS was 73.23	5.56 and 81.22	4.89 (P0.000 for EFS
and OS). The majority of the events in the high risk group happened
in the ﬁrst 100 days [TRM17(41.4%), rejection3(7.3%) and death
from GVHD3(7.3%)]. Using age  7years and liver size  5 cms
we were able to identify a subset of patients in class III (39%) who
have a poor outcome with allogeneic SCT and would beneﬁt from
novel approaches while the remaining patients in Class III had out-
comes comparable to those in Class II.
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Pre-transplant splenectomy has the potential of reducing post
transplant transfusion requirement and hastening engraftment.
Impact of pre-transplant splenectomy in patients with  thalasse-
mia major undergoing an allogeneic SCT has never been ad-
dressed. Between 1991 and 2005, 190 patients underwent 197 HLA
matched related allogeneic SCT for a diagnosis of  thalassemia
major at our center. Patients had undergone a splenectomy at the
discretion of the referring physician. Twenty seven patients (29
transplants) had a pre-transplant splenectomy, they were all Luca-
relli Class III. The outcome of these patients was compared with
73 patients (76 transplants) in Class III who did not have a sple-
nectomy. Patients in the splenectomy group were older (11.7	5.0
years vs 8.5	3.5, P0.003) and had a larger liver size (5.7	1.8 cms
vs 4.4	1.6, P0.000). They were comparable for sex, FM, major
ABO mismatch, SGPT, Ferritin and presence of liver ﬁbrosis. Of
transplants that could be evaluated for engraftment (splenecto-
mized24, rest62), splenectomized patients had a signiﬁcantly
faster time to ANC  500/mm3 (15.4	5.9 days vs 17.5	4,
P0.002) and platelet20000/mm3 (22.5	6.7 days vs 32.5	13.6,
P0.000). The splenectomized group also had a signiﬁcantly re-
duced requirement of blood transfusion in the ﬁrst 100 days post
transplant (5.5	5.1 units vs 7.2	5.4, P0.017) and a trend to
reduced platelet transfusion requirement (59.7	58 units vs
71.8	55.7, P0.075). The rejections (early and late) were compa-
rable between the two groups (20.7% vs 14.5%, P0.55). Among
the splenectomized patients, 17 (63%) died, 1 following primary
graft failure, 7 secondary to RRT and 9 secondary to infective
complications after engraftment (including two late deaths on day
574 and 760 post transplant). On a univariate analysis age
(P0.02), liver size (P0.008) and splenectomy (P0.006) were
signiﬁcantly associated with reduced EFS (event deﬁned as primary
graft failure, rejection or death). On a multivariate analysis, adjust-
ing for age and liver size, splenectomy retained its signiﬁcant
adverse impact on EFS (RR 2.47, 95%CI 1.3 – 4.6, P0.004).
While pre-transplant splenectomy appeared to hasten engraftment
and reduce post transplant transfusion requirement this did not
translate into improved EFS. In this retrospective analysis, pre-
transplant splenectomy appears to be an independent adverse risk
factor in patients with  thalassemia major undergoing a HLA
matched related allogeneic SCT.
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Introduction and objectives: Umbilical cord blood stem cell
transplantation (UCB-SCT) is characterized by a slow myeloid
engraftment and a high incidence of graft failure. In this study we
analyze the role of hematopoietic chimerism analysis in predicting
engraftment after UCB-SCT. Patients and methods: 49 patients
(31 male and 18 female) undergoing UCB-SCT with available
DNA from bone marrow (BM) samples early after transplant
(range, 14-19 days), were included in the study. Median age was 32
years (range, 16-67). Conditioning regimen consisted of thiotepa,
busulfan, cyclophosphamide and anti-thymocytic globulin in 42
patients while in the remaining 7 cyclophosphamide was replaced
by ﬂudarabine. Cyclosporine A and prednisone were used for
GVHD prophylaxis. All patients received G-CSF from day 7.
Hematopoietic chimerism was analyzed in BM samples using
PCR-STR techniques. Results: 21 patients had mixed chimerism
early post-transplant. It was only associated to the number of
CD34 cells infused (0.9 vs 1.5  105/kg; P  0.018). The
probability of myeloid engraftment was 95% at day 57. Proba-
bility of engraftment at 3 weeks was lower in patients with early
mixed chimerism (43% vs 75%; P  0.0037), low number of
CD34 cells (37% vs 84%; P  0.0001), low number of CFU
(48% vs 75%; P  0.06), and low number of CD3 cells (50% vs
75%; P 0.04). Multivariate analysis showed that only early mixed
chimerism (P  0.01) and dose of CD34 cells (P  0.03) were
independent risk factors for myeloid engraftment. Taking into
account these variables, the probability of engraftment at 3 weeks
identiﬁed three groups of patients: i) patients with both mixed
chimerism and low number of CD34 cells (probability of en-
graftment 31%); ii) patients with only mixed chimerism or low
number of CD34 cells (probability of engraftment 61%); and iii)
patients with complete donor chimerism and high number of
CD34 cells (probability of engraftment 85%). The incidence of
primary graft failure was 25% in the ﬁrst group and 3% in the
remaining two groups (P  0.04). Four out of 5 graft failures
occurred in patients with early mixed chimerism with the lowest
values of donor chimerism (less than 60%). Conclusions: Early
hematopoietic chimerism correlates with the kinetic of engraft-
ment after UCB-SCT and identiﬁes a group of patients with high
probability of primary graft failure.
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UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FOR 59 PEDI-
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CB is an attractive source for unrelated transplantation of benign
indications because of the faster and potentially better availability
for minorities. Since most patients are young children, cell dosage
is less of a critical limitation; however, most studies still see a cell
dose effect. Two strategies were employed to maximize cell dose
are plasma depletion (PD) rather than red blood cells depletion
during processing, to forego post-thaw wash, and use of double
cords. A retrospective audited analysis was performed on all pedi-
atric patients with benign disorders transplanted with PD CB.
Patients were deﬁned in two different ways: by age (less than 16
years) and by weight (less than 50kg). When age is used, there were
55 pediatric patients transplanted with 55 PD CB units (4 double
cords); and if classiﬁed by weight, there were 57 patients trans-
planted with 64 PD CB units (7 double cords). When either
deﬁnition was used, the diagnoses were: Thalassemia (29), Aplastic
anemia (7), Wiscott Aldrich Syndrome (5), Severe Combined Im-
munodeﬁciency (5), Osteopetrosis (2), Hemophagocytic Lympho-
histiocytosis (2), Hurler’s Syndrome (2), sickle cell disease,
Chronic Granulomatous Disease, Fanconi Anemia, Leroy I-Cell
Disease, Lymphohistiocytosis, unspeciﬁed metabolic disease, and
Alpha Mannosidosis each (1 each). Transplant characteristics of all
59 patients: median age 4.2 years old (range 0.5-27.4); median
weight 16.8 kg (range 5-49); male 57%; median # HLA ABDR
matches of 5.0 (11-6/6; 19-5/6; 20-4/6; 5-3/6, 1-2/6); median
pre-freeze TNC dose 8.1  107/kg; median post-thaw TNC dose
as reported by TC 7.7  107/kg; median pre-freeze CD34 dose
3.1  105/kg; transplants outside of U.S.- 31 (53%); double unit
transplant 12%; non-myeloablative – 9 (15%); 45% post-thaw
washed (W) and 55% infused without post-thaw wash (NW) of
those with known post-thaw status. Median follow-up time was
218 days (range 4-1,100 days). Kaplan-Meier estimates were used
for outcome analysis and all deaths prior to engraftment were
counted as graft failures. Post-thaw wash did not improve the
safety or efﬁcacy of outcome and appear to delay engraftment. This
series is unusual in its cell dose, which is high even for pediatric
patients, and shows that unrelated PD CBT can be performed
safely with outstanding engraftment and overall survival in a di-
















<16 yo 865%, 19 days 846%, 60 days 43% 165% 845% 786%
Wt
<50 kg 865%, 20 days 846%, 61 days 43% 185% 825% 776%
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ESTIMATION OF HIGH-RESOLUTION HLA-A*, -B*, -C*, -DRB1* HAP-
LOTYPES AND IMPLICATIONS FOR STEM CELL DONOR REGISTRY
PLANNING
Schmidt, A.H.1, Baier, D.1, Stahr, A.1, Rutt, C.1 1DKMS German
Bone Marrow Donor Center, Tuebingen, Germany.
Knowledge of haplotype frequencies of registered potential stem
cell donors is important for both individual donor searches and
questions of strategic donor registry planning. Most published
analyses are based on HLA-A, -B, -DRB1 haplotypes at low/
intermediate resolution level. However, there has been increasing
evidence over the last years that the HLA-C locus and allele
matching are also of relevance for transplantation success.
The analysis of high-resolution haplotypes from donor registry
data is hampered by the fact that registered donors with high-
resolution HLA results for several loci were often selected for
conﬁrmatory typings or donated stem cells. Therefore, samples
that are created by simply choosing donors with high-resolution
HLA results for deﬁned loci from a given donor pool will poten-
tially be affected by a difﬁcult-to-assess selection bias.
We calculated HLA-A*, -B*, -C*, -DRB1* haplotype frequencies
from 7,905 Caucasian donors. These donors were taken from 7,974
DKMS donors who were fully high-resolution typed by sequence-
based typing (SBT) at recruitment. SBT resulted in 4 (or 6) digit
results or in codes in case of ambiguities outside exon 2 (Class II)
or exons 2 and 3 (Class I). 69 donors were excluded from analysis,
mainly because of ambiguities related to the detection of new
alleles. Calculations were performed using the ARLEQUIN soft-
ware package and standard spreadsheet software.
Under the assumption that donor and patient populations have
same haplotype frequency distributions the calculated values can be
used to estimate the probability to ﬁnd at least one matching donor
for patients in need of a stem cell transplant by donor registry size.
The estimated probabilities are 65.0% and 87.3% for registry
sizes of 106 and 107 donors, respectively. If only HLA-A, -B,
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